Drug intelligence / Profile preview

BGB002

Development stage: Preclinical
Lead developer: BerGenBio
Modality: Small Molecules
Administration: Inhalation

Overview

BGB002 is a preclinical small molecule inhibitor developed by BerGenBio, with preclinical development support from Sygnature Discovery. It targets a novel, undisclosed protein that mediates aggressive, drug-resistant tumors, epithelial-to-mesenchymal transition (EMT), and cancer stem cell traits. The target was identified using BerGenBio's proprietary CellSelect RNAi® screening technology.

Targets

PDGFRA (Platelet-derived growth factor receptor alpha)CSF1R (Macrophage colony-stimulating factor receptor)KIT (c-KIT proto-oncogene receptor tyrosine kinase)PDGFRB (Platelet-derived growth factor receptor beta)

Beyond the preview

Go deeper on BGB002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BGB002.

Explore the full profile